<DOC>
	<DOCNO>NCT00311597</DOCNO>
	<brief_summary>RATIONALE : Extracranial stereotactic radiosurgery may able send x-ray directly tumor cause less damage normal tissue . PURPOSE : This phase I/II trial study side effect best dose extracranial stereotactic radiosurgery see well work treat patient solid tumor .</brief_summary>
	<brief_title>Extracranial Stereotactic Radiosurgery Treating Patients With Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : Primary - Establish maximum tolerate dose ( MTD ) extracranial stereotactic radiosurgery patient isolated tumor . ( Phase I ) - Determine minimum dose required local control . ( Phase II ) Secondary - Determine radiographic response rate . - Determine median time progression treat tumor . - Evaluate toxicity treatment . - Evaluate cause death . OUTLINE : This phase I dose-escalation study follow phase II open-label study . Patients stratify accord tumor size . - Phase I : Patients undergo stereotactic radiosurgery one lesion . Cohorts 3-6 patient undergo escalate dos stereotactic radiosurgery maximum tolerate dose ( MTD ) determine . The MTD define dose 33 % patient experience dose-limiting toxicity within 3 month treatment . - Phase II : Patients undergo stereotactic radiosurgery one lesion MTD dose local control 3 month ≥ 80 % , determined phase I . After completion study treatment , patient follow 1 month , 3 month , every 3 month thereafter . PROJECTED ACCRUAL : At least 48 patient accrue study .</detailed_description>
	<criteria>DISEASE CHARACTERISTICS : Presence wellcircumscribed tumor contrastenhanced CT scan MRI Maximum diameter 6 cm PATIENT CHARACTERISTICS : Life expectancy ≥ 3 month Not pregnant Fertile patient must use effective contraception Negative pregnancy test Must able tolerate CT scan MRI contrast PRIOR CONCURRENT THERAPY : At least 3 week since prior chemotherapy immunotherapy No prior treatment study No chemotherapy immunotherapy 4 week completion study treatment No concurrent externalbeam radiotherapy overlap radiosurgicallytreated volume ( include lowdose region )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>